Literature DB >> 15528468

Xanthine oxidoreductase is an endogenous regulator of cyclooxygenase-2.

Toshio Ohtsubo1, Ilsa I Rovira, Matthew F Starost, Chengyu Liu, Toren Finkel.   

Abstract

Xanthine oxidoreductase (XOR) is the enzyme responsible for the final step in purine degradation resulting in the generation of uric acid. Here we have generated mice deficient in XOR. As expected, these animals lack tissue XOR activity and have low to undetectable serum levels of uric acid. Although normal at birth, XOR-/- mice fail to thrive after 10 to 14 days, and most die within the first month. The cause of death appears to be a form of severe renal dysplasia, a phenotype that closely resembles what has been observed previously in cyclooxygenase-2 (COX-2)-deficient mice. We further demonstrate that in the first month of life, a period in which the mouse kidney is undergoing rapid maturation and remodeling, wild-type mice exhibit an approximately 30-fold increase in renal XOR activity, with a corresponding induction of COX-2 expression. In contrast, during this same period, XOR-/- animals fail to augment renal COX-2 expression. Finally, we show that in vitro and in vivo, uric acid can stimulate basal COX-2 expression. These results demonstrate that XOR activity is an endogenous physiological regulator of COX-2 expression and thereby provide insight into previous epidemiological evidence linking elevated serum uric levels with systemic hypertension and increased mortality from cardiovascular diseases. In addition, these results suggest a novel molecular link between cellular injury and the inflammatory response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528468     DOI: 10.1161/01.RES.0000149571.96304.36

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  37 in total

1.  Uric acid promotes an acute inflammatory response to sterile cell death in mice.

Authors:  Hajime Kono; Chun-Jen Chen; Fernando Ontiveros; Kenneth L Rock
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

2.  Xanthine oxidoreductase depletion induces renal interstitial fibrosis through aberrant lipid and purine accumulation in renal tubules.

Authors:  Toshio Ohtsubo; Kiyoshi Matsumura; Kanae Sakagami; Koji Fujii; Kazuhiko Tsuruya; Hideko Noguchi; Ilsa I Rovira; Toren Finkel; Mitsuo Iida
Journal:  Hypertension       Date:  2009-08-10       Impact factor: 10.190

3.  Inhibition of xanthine oxidase by the aldehyde oxidase inhibitor raloxifene: implications for identifying molybdopterin nitrite reductases.

Authors:  E R Weidert; S O Schoenborn; N Cantu-Medellin; K V Choughule; J P Jones; E E Kelley
Journal:  Nitric Oxide       Date:  2014-01-07       Impact factor: 4.427

Review 4.  Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication.

Authors:  Jan-Bernd Funcke; Philipp E Scherer
Journal:  J Lipid Res       Date:  2019-06-17       Impact factor: 5.922

Review 5.  Uric acid as a target of therapy in CKD.

Authors:  Diana I Jalal; Michel Chonchol; Wei Chen; Giovanni Targher
Journal:  Am J Kidney Dis       Date:  2012-10-09       Impact factor: 8.860

6.  Alcohol abuse is associated with enhanced pulmonary and systemic xanthine oxidoreductase activity.

Authors:  Mehdi A Fini; Jeanette Gaydos; Alicia McNally; Vijaya Karoor; Ellen L Burnham
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-24       Impact factor: 5.464

7.  Fatty acid nitroalkenes ameliorate glucose intolerance and pulmonary hypertension in high-fat diet-induced obesity.

Authors:  Eric E Kelley; Jeff Baust; Gustavo Bonacci; Franca Golin-Bisello; Jason E Devlin; Claudette M St Croix; Simon C Watkins; Sonia Gor; Nadiezhda Cantu-Medellin; Eric R Weidert; Jefferson C Frisbee; Mark T Gladwin; Hunter C Champion; Bruce A Freeman; Nicholas K H Khoo
Journal:  Cardiovasc Res       Date:  2014-01-02       Impact factor: 10.787

Review 8.  Xanthine oxidoreductase-catalyzed reduction of nitrite to nitric oxide: insights regarding where, when and how.

Authors:  Nadiezhda Cantu-Medellin; Eric E Kelley
Journal:  Nitric Oxide       Date:  2013-02-27       Impact factor: 4.427

9.  Migratory activity of human breast cancer cells is modulated by differential expression of xanthine oxidoreductase.

Authors:  Mehdi A Fini; David Orchard-Webb; Beata Kosmider; Jeremy D Amon; Robert Kelland; Gayle Shibao; Richard M Wright
Journal:  J Cell Biochem       Date:  2008-11-01       Impact factor: 4.429

10.  The PRY/SPRY/B30.2 domain of butyrophilin 1A1 (BTN1A1) binds to xanthine oxidoreductase: implications for the function of BTN1A1 in the mammary gland and other tissues.

Authors:  Jaekwang Jeong; Anita U Rao; Jinling Xu; Sherry L Ogg; Yetrib Hathout; Catherine Fenselau; Ian H Mather
Journal:  J Biol Chem       Date:  2009-06-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.